NCT02873286View on ClinicalTrials.gov

RSV-MVA-BN Vaccine Phase II Trial in ≥ 55 Year Old Adults

PHASE2CompletedINTERVENTIONAL
Enrollment

420

Participants

Timeline

Start Date

September 30, 2016

Primary Completion Date

December 31, 2018

Study Completion Date

December 31, 2018

Conditions
Respiratory Syncytial Virus Infections
Interventions
BIOLOGICAL

MVA-BN-RSV

MVA-mBN294B

OTHER

Placebo

Tris Buffered Saline, sterile

Trial Locations (12)

13760

Regional Clinical Research Associates, Endwell

13901

United Medical Associates, Binghamton

20850

Optimal Research, Rockville

30281

Clinical Research Atlanta, Stockbridge

31406

Meridian Clinical Research, Savannah

32162

Compass Research, The Villages

44122

Rapid Medical Research, Cleveland

61614

Optimal Research, Peoria

63110

Washington University in St. Louis, School of Medicine, St Louis

76104

Ventavia Research Group, Fort Worth

92108

Optimal Research, San Diego

96001

Paradigm Research, Redding

Sponsors

Lead Sponsor

Bavarian Nordic
All Listed Sponsors
lead

Bavarian Nordic

INDUSTRY

NCT02873286 - RSV-MVA-BN Vaccine Phase II Trial in ≥ 55 Year Old Adults | Biotech Hunter | Biotech Hunter